CPIC rec 8093545 [Strong]: If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093545 [Strong]: If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093547 [Strong]: If patient is carbamazepine-naïve, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093547 [Strong]: If patient is carbamazepine-naïve, do not use carbamazepine. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093554 [Optional]: If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093554 [Optional]: If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
CPIC rec 8093564 [Optional]: The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future. CPIC pair-level A (HLA-A, HLA-B and Carbamazepine and Oxcarbazepine) [PMID 23695185, 29392710]
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)-100+100
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature